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Highlights 29 
 Decreased total antioxidant capacity, measured by CUPRAC and TEAC assays, 30 
was demonstrated in sera from dogs with IBD. 31 
 Serum thiol and PON1 activity was significantly decreased in sera from dogs 32 
with IBD compared with healthy dogs. 33 
 Oxidative damage in dogs with IBD was demonstrated by increased serum FOX, 34 
ROS and TBARS. 35 
 36 
Abstract 37 
The objective of this study was to evaluate and compare a panel of various 38 
serum biomarkers evaluating both the antioxidant response and oxidative damage in 39 
dogs with idiopathic inflammatory bowel disease (IBD). Eighteen dogs with IBD and 40 
20 healthy dogs were enrolled in the study. Trolox equivalent antioxidant capacity 41 
(TEAC), cupric reducing antioxidant capacity (CUPRAC), ferric reducing ability of the 42 
plasma (FRAP), total thiol concentrations, and paraoxonase 1 (PON1) activity were 43 
evaluated in serum to determine antioxidant response. To evaluate oxidative status, 44 
ferrous oxidation-xylenol orange (FOX), thiobarbituric acid reactive substances 45 
(TBARS) and reactive oxygen species production (ROS) concentrations in serum were 46 
determined.  47 
 48 
Mean concentrations of all antioxidant biomarkers analysed, with exception of 49 
FRAP, were significantly lower (P <0.0001) in the sera of dogs with IBD than in 50 
healthy dogs. The oxidant markers studied were significantly higher (P <0.0001) in sera 51 
of dogs with IBD than in healthy dogs. These findings support the hypothesis that 52 
oxidative stress could play an important role in the pathogenesis of canine IBD.  53 
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Introduction 56 
Idiopathic inflammatory bowel disease (IBD) is characterised by persistent or 57 
recurrent activation of the mucosal immune system accompanied by infiltrations of 58 
inflammatory cells in the intestinal mucosa (Allenspach et al., 2007; Simpson and 59 
Jergens, 2011). It is the most common cause of chronic intestinal disease in dogs, and 60 
results in diverse and often debilitating clinical signs (Jergens et al., 2003; Allenspach et 61 
al., 2016). 62 
 63 
The pathogenesis of IBD in dogs is not completely understood; however it is 64 
believed that intestinal inflammation results from a dysregulated immune response to 65 
intestinal antigens (Allenspach et al., 2010). There is evidence that oxidative stress 66 
plays an important role in the pathogenesis of IBD in human patients particularly in the 67 
initiation and perpetuation of inflammation and in subsequent tissue damage. Oxidative 68 
stress occurs when there is a marked imbalance between the production of reactive 69 
oxygen species (ROS) and their removal by antioxidants (Rezaie et al., 2007). Recent 70 
studies suggest that oxidative stress could also represent a significant factor in the 71 
pathogenesis of IBD in dogs. One study that evaluated the metabolomics profile in dogs 72 
with IBD using an untargeted metabolomics approach suggested the presence of 73 
oxidative stress and a functional alteration of the GI microbiota in dogs with IBD, 74 
which persisted even in the face of a clinical response to medical therapy (Minamoto et 75 
al., 2014). Other recent studies have reported that various serum antioxidant biomarkers, 76 
such as Trolox equivalent antioxidant capacity (TEAC), cupric reducing antioxidant 77 
capacity (CUPRAC) and paraoxonase 1 (PON1), were decreased in the sera of dogs 78 
with IBD (Rubio et al., 2016a,b; Segarra et al., 2016), again suggesting that oxidative 79 
stress could play an important role in the pathogenesis of canine IBD. 80 
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 81 
The purpose of this study was to evaluate and compare a panel of various serum 82 
biomarkers evaluating both the antioxidant response and oxidative damage response in 83 
sera from dogs with IBD. These included previously the described antioxidant serum 84 
biomarkers TEAC, CUPRAC and PON1, and additional antioxidants that have not 85 
previously been studied in canine IBD, such as ferric reducing ability of plasma (FRAP) 86 
and total serum thiol concentrations. To investigate oxidative damage, we measured 87 
ferrous oxidation-xylenol orange (FOX) and thiobarbituric acid reactive substances 88 
(TBARS), which measures products of lipid peroxidation in serum. Finally, we 89 
measured serum concentrations of reactive oxygen species. 90 
 91 
Material and methods 92 
Animals 93 
In this retrospective study, a group of 18 dogs diagnosed with IBD at the Royal 94 
Veterinary College (RVC), London, were included. Dogs with a history typical for 95 
chronic enteropathy (≥3 weeks of vomiting, diarrhea or both, with or without weight 96 
loss) were included. The diagnosis of chronic enteropathy was confirmed based on 97 
established criteria (no clinically relevant abnormalities on routine hematology, serum 98 
biochemistry; trypsin‐like immunoreactivity [TLI], canine pancreatic lipase [cPL] and 99 
adrenocorticotropic hormone [ACTH]‐stimulation test results within the reference 100 
ranges; no abnormalities on abdominal imaging [radiographs, abdominal ultrasound 101 
examination or both]; Allenspach et al., 2007). The histopathological criteria for IBD 102 
were based on the guidelines for evaluation of gastrointestinal inflammation in 103 
companion animals, as established by Washabau et al. (2010). In all cases biopsies were 104 
obtained and reviewed by a board-certified pathologist. 105 
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 106 
In addition, 20 clinically healthy dogs were included in this study as a control 107 
group. 108 
 109 
Archived sera from healthy dogs and those with IBD and biopsy samples were 110 
originally obtained in 2007 for diagnostic purposes only and were residual samples, 111 
stored and available in the RVC archive. They were originally obtained with informed 112 
owner consent under the Veterinary Surgeons Act (residual clause) and approved by the 113 
RVC Ethics and Welfare Committee and were frozen immediately after blood sampling 114 
and stored at -80 ºC until further analysis. 115 
 116 
Antioxidant capacity 117 
The TEAC assay, based on the inhibition of the radical ABTS by the sample, 118 
was performed according to the assay described by Arnao et al. (1996) validated by 119 
Rubio et al. (2016a). The CUPRAC assay, based on the capacity of the sample in 120 
reducing Cu(II) to Cu(I), was performed as previously described for use in canine serum 121 
(Rubio et al., 2016b). The FRAP assay was performed following the method by Benzie 122 
and Strain (1996) which measures the ferric to ferrous ion reduction by the sample.  123 
 124 
Serum thiol was determined according to the method by Jocelyn (1987), and 125 
serum PON1 activity was analysed following a previously described method for use in 126 
canine serum (Tvarijonaviciute et al., 2012).  127 
 128 
All analyses were performed at Murcia University using an automated 129 
biochemistry analyser (Olympus AU600 Automatic Chemistry Analyser, Olympus). All 130 
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assays showed inter- and intra-assay imprecision of <15%. Lower detection limits of 131 
TEAC, CUPRAC and FRAP were 0.090, 0.003, and 0.031 mmol/L, respectively. The 132 
lower detection limit of serum thiol and PON1 were 4.0 µmol/L and 0.6 U/mL, 133 
respectively.  134 
 135 
Oxidant biomarkers 136 
The FOX assay was based on the automated method described by Arab and 137 
Steghens (2004) and performed using the Olympus AU600 Automatic Chemistry 138 
Analyser (Olympus). The TBARS assay was determined following the method by 139 
Buege and Aust (1978) using a microplate reader (Powerwave XS, Biotek instruments).  140 
 141 
Reactive oxygen species (ROS) were estimated by luminol-mediated 142 
chemiluminescence assay (Vong et al., 2014) using a microplate reader (Victor 2 1420 143 
Multilabel Counter; PerkinElmer, Finland) and expressed in counts per second (cps). 144 
All oxidant assays showed inter- and intra-assay imprecision less than 15% when 145 
evaluated in our laboratory. In addition, the lower detection limits of FOX and TBARS 146 
were 55.91 and 0.81 µmol/L, respectively. The ROS assay showed a lower detection 147 
limit of of 1,300 cps. 148 
 149 
Statistical analysis 150 
Data were analysed using Graphpad Prism software (version 5 for Windows). 151 
Concentrations of antioxidants and oxidant biomarkers were compared between dogs 152 
with IBD and healthy control dogs. The results for each parameter were evaluated for 153 
normality using the Shapiro-Wilk test. Thiol, PON1, TBARS and ROS results were not 154 
normally distributed, therefore they were presented as median and interquartile range 155 
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(IQR). Normally distributed data were presented as means ± standard deviation. We 156 
determined statistical differences between healthy dogs and dogs with IBD using 157 
unpaired t test (normally distributed data) and Mann Whitney U test (not normally 158 
distributed data). Correlations between variables were determined using Spearman 159 
correlation analysis. A P-value (two-tailed) of <0.05 was taken as statistically 160 
significant in all cases.  161 
  162 
Results 163 
Animals  164 
The 18 dogs with IBD included Border collie (n=1), Boxer (n=3), Cocker 165 
spaniel (n=2), East-European shepherd (n=1), Greyhound (n=1), Labrador (n=2), Mixed 166 
breed (n=1), Old English sheepdog (n=1), Polish Lowland sheepdog (n=1), Rottweiler 167 
(n=1), Schnauzer (n=1), Staffordshire terrier (n=2), West Highland white terrier (n=1). 168 
Their ages ranged from 7 months to 11 years; eight were females (n=6 spayed; n=2 169 
intact) and 10 were males (n=4 neutered; n=6 intact). The clinical status of each dog 170 
was evaluated at the time of diagnosis using the canine chronic enteropathy clinical 171 
activity index (CCECAI) scoring system established by Allenspach et al. (2007), which 172 
is based on nine variables, including attitude and activity, appetite, vomiting, stool 173 
consistency, stool frequency, weight loss, ascites, pruritus and serum albumin 174 
concentration. Based on CCECAI, the disease was mild (score 4-5) in two dogs, 175 
moderate (score 6-8) in 11 dogs, severe (score 9-11) in two dogs, and very severe (score 176 
≥12) in three dogs.  177 
 178 
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Histopathologic findings of intestinal mucosal biopsies showed in all cases a 179 
lympho-plasmacytic inflammation, in some cases with eosinophils. There was no 180 
neutrophilic or macrophagic inflammation in any case. 181 
 182 
The 20 control dogs consisted of various breeds (Mixed breed, Staffordshire 183 
terrier, Italian Spinone, Labrador, Cavalier King Charles spaniel, English Springer 184 
spaniel, Akita Inu, Golden retriever, Border collie, Dogue de Bordeaux, Rottweiler, 185 
Great Dane, Japanese Spitz, Leonberger).  Their ages ranged from 2 to 13 years; seven 186 
were female (n=6 spayed; n=1 intact) and 13 were male (n=11 neutered; n=2 intact). 187 
 188 
Antioxidant response 189 
Dogs with IBD had lower TEAC concentrations (0.35±0.06 vs. 0.51±0.04 190 
mmol/L; P <0.0001), lower CUPRAC concentrations (0.3±0.05 vs. 0.44±0.05 mmol/L; 191 
P <0.0001), lower serum thiol concentrations (median, 63; IQR, 34-94 vs. median, 245; 192 
IQR, 216-277 µmol/L; P <0.0001), and lower PON1 activity than control dogs (median, 193 
2.2; IQR, 1.7-2.8 vs. median, 3.5; IQR, 3.1-3.8 IU/mL; P <0.0001; Fig. 1). 194 
 195 
However, serum FRAP did not differ between dogs with IBD and control dogs 196 
(0.41±0.09 vs. 0.42±0.07 mmol/L; P =0.6459).  197 
 198 
Oxidant biomarkers 199 
Dogs with IBD had higher serum ROS counts (median, 8,861; IQR, 5,900-200 
14,763 cps vs. median, 1,502; IQR, 1,384-1,648 cps; P <0.0001), higher FOX 201 
concentrations (148±65 vs. 72±13 µmol/L; P <0.0001) and higher TBARS 202 
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concentrations than control dogs (median, 8.0; IQR, 5.9-10.5 vs. median, 2.4; IQR: 1.9-203 
2.8 µmol/L; P <0.0001; Fig. 2).  204 
 205 
Correlation study 206 
We observed correlations between all antioxidant biomarkers except for FRAP 207 
and TEAC, and FRAP and CUPRAC (Table 1). The highest correlations ( > 0.90) 208 
were observed between TEAC, CUPRAC and serum thiol.  209 
 210 
Similarly, all oxidant biomarkers were positively correlated, with the highest 211 
coefficient of correlation being between TBARS and ROS ( = 0.84; P <0.001). In 212 
addition, TBARS and ROS correlated negatively with TEAC, CUPRAC, and PON1 (all 213 
 ≤ 0.45; P <0.01). A negative correlation was also observed between all oxidant 214 
biomarkers and serum thiol (all  ≤ 0.54; P <0.001). 215 
 216 
The CCECAI was not correlated with any of the biomarkers studied (all P 217 
≥0.05).  218 
 219 
Discussion 220 
Our study, evaluating the oxidative stress in dogs with IBD compared to healthy 221 
control dogs using a comprehensive panel of serum biomarkers, suggests increased 222 
oxidative stress status in canine IBD.  223 
 224 
Serum TEAC and CUPRAC were significantly reduced in dogs with IBD 225 
compared with healthy dogs. These results corroborate recent studies in dogs (Rubio et 226 
al., 2016a,b; Segarra et al., 2016). Furthermore, Rubio et al. (2016a) observed similar 227 
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decreases (about 30%) in the TEAC concentration in dogs with IBD, as we did in the 228 
present study. In this cohort of dogs, dogs with IBD had mean CUPRAC serum 229 
concentrations that were 33% lower than in healthy dogs, compared to a 17% decrease 230 
observed by Rubio et al. (2016b). Decreased TEAC and individual antioxidant (biotin, 231 
folate, β-carotene, and vitamins A, C, and B) concentrations have previously been 232 
reported in human patients with ulcerative colitis (UC; Fernandez-Banares et al., 1989; 233 
Geerling, 1999; Aslan et al., 2011). The decreased antioxidant response in dogs with 234 
IBD could be due to severe, persistent oxidative stress that depletes antioxidant 235 
resources and overtakes the ability of the body to produce more antioxidants (Rezaie et 236 
al., 2007). We failed to detect a difference in serum FRAP between healthy dogs and 237 
dogs with IBD. This might be explained by the different individual antioxidants that 238 
contribute to serum FRAP compared with other total antioxidant capacity (TAC) assays. 239 
Ascorbic acid, α-tocopherol and principally uric acid are the contributors to FRAP in 240 
humans, whereas thiols and albumin are the main contributors to CUPRAC and TEAC. 241 
Therefore, we recommend that several different methods be used to measure TAC in 242 
biological samples, because individual assays have different biochemical bases, 243 
resulting in different results and interpretations (Cao and Prior, 1998; Hetyey et al., 244 
2007; Jansen and Ruskovska, 2013).  245 
 246 
Studies have shown that mucosal thiol proteins are targets of oxidative injury 247 
(Grisham et al., 1990). In the present study, serum thiol and PON1 were also 248 
determined as individual antioxidants and both were significantly diminished in dogs 249 
with IBD. Paraoxonase 1 (PON1) is widely distributed among tissues, including the 250 
intestine. This protein is considered to be an antioxidant enzyme as it hydrolyses lipid 251 
peroxides, in addition to its anti-inflammatory role in disease (Ceron et al., 2014). One 252 
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of the explanations for decreased PON1 activity could be its inactivation due to an 253 
exacerbated oxidative environment (Nguyen and Sok, 2003). Our results are in 254 
agreement with other studies that reported diminished PON1 activity in dogs with IBD 255 
and human patients with IBD (Baskol et al., 2006; Boehm et al., 2009; Segarra et al., 256 
2016). In addition, there is evidence that diminished PON1 activity could also be a 257 
consequence of a reduced number of the free SH groups on PON1, because of 258 
exposition to oxygen free radicals (Jaouad et al., 2006), which could explain the high 259 
correlation between serum PON1 activity and total serum thiol found in this study.  260 
 261 
We demonstrated increased ROS and products of lipid peroxidation in the sera 262 
of dogs with IBD by TBARS and FOX assays. These results are in agreement with 263 
reports of IBD in humans (Levy et al., 2000; Sampietro et al., 2002; Baskol et al., 264 
2006). It has been reported that phagocytic cells (neutrophils and macrophages) isolated 265 
from inflamed intestinal tissue in human patients with IBD release large amounts of 266 
ROS during stimulation that could act locally or be secreted into the circulation to 267 
produce different systemic effects (Kitahora et al., 1988; Alzoghaibi, 2013). However, 268 
in our study, inflamed intestinal mucosa in the dogs with IBD contained lymphocytes 269 
and plasma cells, which could suggest that these cells might also be a source of 270 
systemic ROS, as has been suggested in humans (Lantow et al., 2006). Nevertheless, 271 
studies using larger group sizes are needed to evaluate the association between the type 272 
of cells detected in the inflamed mucosa of the dogs with IBD and the systemic 273 
concentrations of oxidants (ROS and lipid peroxides) during the disease. 274 
 275 
The relatively low number of dogs with IBD in our study might have limited our 276 
ability to detect correlations between the various serum biomarkers and clinical disease 277 
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activity. However, our data show that antioxidants, which act to control oxidative stress, 278 
are decreased, and oxidants generated in association with oxidative stress are increased 279 
in dogs with IBD. These findings could help explain the pathophysiology of the disease. 280 
However, further studies with larger group sizes are necessary to evaluate the potential 281 
of these markers as possible predictors of disease and biomarkers for treatment 282 
monitoring.  283 
 284 
Although we did not determine the stability of the oxidant and antioxidants we 285 
measured in canine sera, previous reports demonstrated that antioxidants were stable in 286 
human serum stored at -80 ºC for at least 1 year (Jansen et al., 2013). In addition, the 287 
values of the control group were inside the reference values of our laboratory, 288 
determined with fresh samples. However, possible changes during the long storage of 289 
the samples in any of the analytes measured cannot be disregarded and this should be 290 
considered as a limitation of our study. 291 
 292 
Conclusions 293 
Our study demonstrated the presence of oxidative stress in dogs with IBD. Based 294 
on our results, a profile including biomarkers of total antioxidant status such as TEAC 295 
and CUPRAC, individual antioxidant biomarkers such as PON1 and thiol, and 296 
biomarkers of oxidant status measuring lipid peroxidation, such as FOX, or TBARS, or 297 
directly measuring ROS production, might be useful in the comprehensive evaluation of 298 
the oxidative stress response in dogs with IBD. 299 
 300 
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 467 
Fig. 1. Comparisons of antioxidant biomarkers in healthy dogs and dogs with IBD. The 468 
plots show median (line within box), 25th and 75th percentiles (box) and minimum and 469 
maximum values (whiskers). TEAC, Trolox equivalent antioxidant capacity; CUPRAC, 470 
cupric reducing antioxidant capacity; FRAP, ferric reducing ability of plasma; PON1, 471 
paraoxonase 1. 472 
 473 
Fig. 2. Comparisons of oxidant biomarkers in healthy dogs and dogs with IBD. The 474 
plots show median (line within box), 25th and 75th percentiles (box) and minimum and 475 
maximum values (whiskers). ROS, reactive oxygen species; FOX, ferrous oxidation-476 
xylenol orange; TBARS, thiobarbituric acid reactive substances. 477 
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Table 1. Spearman correlation coefficients, levels of statistical significance (95% 478 
confidence intervals) between all biomarkers studied. 479 
 TEAC  CUPRA
C  
FRAP  Thiol  PON1  FOX  TBARS  
CUP
RAC 
0.92***  
(0.84 to 
0.95)  
      
FRAP 0.26  
(- 0.07 to 
0.55) 
0.27  
(- 0.07 to 
0.55) 
     
Thiol  0.90***  
(0.81 to 
0.95) 
0.90***  
(0.81 to 
0.95) 
0.04  
(- 0.30 to 
0.37) 
    
PON1  0.68***  
(0.45 to 
0.82) 
0.72***  
(0.51 to 
0.85) 
0.34*  
(0.01 to 
0.61) 
0.65***  
(0.41 to 
0.81) 
   
FOX  -0.40* 
 (-0.65 to 
-0.08) 
-0.39*  
(-0.64 to 
-0.06) 
0.46**  
(0.16 to 
0.69) 
-0.54*** 
(-0.74 to 
-0.26) 
-0.20  
(-0.50 to 
0.13) 
  
TBA
RS 
-0.54***  
(-0.74 to 
-0.26)  
-0.59***  
(-0.77 to 
-0.32) 
0.12 
(-0.22 to 
-0.44) 
-0.65***  
(-0.81 to 
-0.41) 
-0.45**  
(-0.68 to 
-0.14) 
0.74***  
(0.54 to 
-0.86) 
 
ROS -0.70*** 
(-0.84 to 
-0.49) 
-0.77***  
(-0.88 to 
-0.58) 
-0.07  
(-0.40 to 
-0.27) 
-0.77*** 
 (-0.88 to 
-0.60) 
-0.65*** 
 (-0.81 to 
-0.40) 
0.61***  
(0.35 to 
0.78) 
0.84***  
(0.70 to 
0.91) 
* P <0.05; ** P <0.01; *** P <0.001. 480 
CUPRAC, cupric reducing antioxidant capacity; FRAP, ferric reducing ability of 481 
plasma; FOX, ferrous oxidation-xylenol orange; PON1, paraoxonase 1; ROS, reactive 482 
oxygen species; TBARS, thiobarbituric acid reactive substances; TEAC, Trolox 483 
equivalent antioxidant capacity. 484 
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